0001209191-15-040135.txt : 20150507 0001209191-15-040135.hdr.sgml : 20150507 20150507175847 ACCESSION NUMBER: 0001209191-15-040135 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150501 FILED AS OF DATE: 20150507 DATE AS OF CHANGE: 20150507 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carter Martha J. CENTRAL INDEX KEY: 0001213040 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 15843345 MAIL ADDRESS: STREET 1: C/O AEGERION PHARMACEUTICALS, INC. STREET 2: 89 HEADQUARTERS PLAZA, SUITE 1212 CITY: MORRISTOWN STATE: NJ ZIP: 07960 FORMER NAME: FORMER CONFORMED NAME: CARTER MARTHA J DATE OF NAME CHANGE: 20030106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-05-01 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001213040 Carter Martha J. C/O AEGERION PHARMACEUTICALS, INC. ONE MAIN STREET, SUITE 800 CAMBRIDGE MA 02142 0 1 0 0 See Remarks Stock Option (right to buy) 23.61 2015-05-01 4 A 0 13000 0.00 A 2025-05-01 Common Stock 13000 13000 D Restricted Stock Units 2015-05-01 4 A 0 3000 0.00 A Common Stock 3000 3000 D The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant. 25% of the shares of common stock underlying this stock option award will vest on May 1, 2016, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through May 1, 2019, subject to the Reporting Person's continued employment with the Issuer. Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 1, 2016, 33.33% of the units vesting on May 1, 2017, and 33.33% of the units vesting on May 1, 2018, subject to the Reporting Person's continued employment with the Issuer. Chief Regulatory Officer and Senior Vice President /s/ Anne Marie Cook, attorney-in-fact 2015-05-07